ValuEngine cut shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) from a hold rating to a sell rating in a research report released on Tuesday morning.
ONCE has been the subject of several other reports. Cantor Fitzgerald dropped their price objective on Spark Therapeutics from $105.00 to $94.00 and set a buy rating for the company in a report on Friday, October 13th. Cowen and Company restated a buy rating and set a $95.00 target price on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Barclays PLC boosted their target price on Spark Therapeutics from $104.00 to $107.00 and gave the stock an overweight rating in a research report on Friday, October 13th. Chardan Capital restated a buy rating and set a $100.00 target price on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, Zacks Investment Research upgraded Spark Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have given a buy rating to the company’s stock. Spark Therapeutics currently has a consensus rating of Buy and an average target price of $90.36.
Shares of Spark Therapeutics (NASDAQ ONCE) opened at $73.93 on Tuesday. Spark Therapeutics has a twelve month low of $47.03 and a twelve month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.07) earnings per share. sell-side analysts predict that Spark Therapeutics will post -7.67 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/spark-therapeutics-inc-once-cut-to-sell-at-valuengine/1782560.html.
In other Spark Therapeutics news, insider Barge Joseph La sold 3,309 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $71.31, for a total value of $235,964.79. Following the sale, the insider now owns 8,146 shares in the company, valued at approximately $580,891.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.54, for a total value of $1,430,800.00. Following the completion of the sale, the chief executive officer now owns 250,000 shares in the company, valued at approximately $17,885,000. The disclosure for this sale can be found here. Insiders sold a total of 1,099,659 shares of company stock worth $92,457,658 in the last 90 days. Company insiders own 7.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its stake in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Spark Therapeutics during the 2nd quarter worth approximately $143,000. BNP Paribas Arbitrage SA raised its stake in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,449 shares in the last quarter. Pacad Investment Ltd. raised its stake in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Spark Therapeutics during the 3rd quarter worth approximately $225,000. Institutional investors own 77.94% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with our FREE daily email newsletter.